Julie Wei

Ultragenyx Pharmaceutical Inc.

Dr. Wei is the Associate Director of Analytical Development at Ultragenyx Gene Therapy. Dr. Wei has her Ph.D. from Brandeis University, where she studied protein structure and functional relationship with NMR, and is the discoverer of the mechanism of O2-CO2 conversion in P450 proteins. She has held patent in processing in the area of cell culture SEC method, cell-culture CE-MS method, in-silico formulation screening, and a patent in preventative therapy in Alzheimer’s disease. Prior to her role at Ultragenyx, Dr. Wei was the Director of Analytical Formulation Sciences at HJB, a Consultant for biotech companies, and she served ten years in the department of Technology Development at Biogen. Her current focus at Ultragenyx, is the development of chemical and biophysical methods suited for characterization of adeno-associated virus for gene delivery therapy. The methods she developed at Ultragenyx include: SEC, CE-SDS, UV, AUC, and LC-MS, which all became quality methods for the release of those products.